Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.5 Million Public Offering

Press Release – New York, NY – December 12, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, in an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant.

The SRFC team was led by partners Gregory Sichenzia and Avital Perlman and associates Christian Lichtenberger and Benasz Hansotia.